# Johnson & Johnson (JNJ) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/JNJ
## Company Profile
- Ticker: JNJ
- Exchange: NYSE
- Sector: Biopharma, Small Molecule Drugs, Nucleic Acid Drugs, Novel Therapies
- Location: United States
- Tags: MedTech, Novel Therapies, Small Molecule Drugs, Nucleic Acid Drugs, Oncology, CNS
## Stock Data
- Close: 260.86 USD
- Market cap: 536544590666.18994 USD
- Last updated: 2026-08-12
## Business Overview
Johnson & Johnson is a global healthcare leader spanning innovative medicines and medtech. Its scale, diversification, and broad therapeutic reach make it one of the most important names in the sector.
## Why The Stock Is Moving

As of Aug 12, 2026, JNJ closed up 0.41% at $260.86. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NYSE, J&J has a global footprint across pharmaceuticals and medical devices. It is a diversified healthcare company rather than a pure biotech or single-segment platform.

## Business Model

The company generates value through product sales across medicines, surgery, orthopedics, and medtech franchises. Investors focus on pipeline depth, launch execution, and the ability to replace mature products with new growth drivers.

## Landscape Position

J&J sits above the biotech cycle as a diversified healthcare bellwether. It is less volatile than development-stage biotech, but regulatory and pipeline updates still matter because they shape long-term growth expectations.

## Future Catalysts

- Johnson & Johnson’s near-term watchpoints are the TAR-210 uro-oncology program, RYBREVANT FASPRO rollout, and any further updates that show whether the company can keep turning new assets into commercial momentum. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.

## Recent News
- No recent company news available.